Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + DVd in high-risk relapsed/refractory myeloma (real-world, multicenter)
ChiCTR2200058238Phase 4Not yet recruiting
- Sponsor
- Beijing Chaoyang Hospital, Capital Medical University
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of selinexor in multiple myeloma (MM), sponsored by Beijing Chaoyang Hospital, Capital Medical University. Primary endpoint: Total effective rate. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2200058238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058238.